|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RED CELLS
From the Departments of Pharmacology and Medicine,
School of Medicine, Center for Thrombosis and Hemostasis and Lineberger
Comprehensive Cancer Center, The University of North Carolina at Chapel
Hill.
The adhesive protein thrombospondin (TSP) potentially
mediates sickle (SS) red blood cell (RBC) adhesion to the blood vessel wall, thereby contributing to vaso-occlusive crises in sickle cell
disease. We previously reported that SS RBCs bind to immobilized TSP
under flow conditions, whereas normal (AA) red cells do not. However,
the SS RBC receptors that mediate this interaction are largely unknown.
Here it is reported that integrin-associated protein (IAP), or CD47,
mediates the adhesion of these cells to immobilized TSP under both flow
and static conditions. A peptide derived from the C-terminal IAP
binding site of TSP also supports sickle cell adhesion; adhesion to
this peptide or to TSP is inhibited specifically by the anti-IAP
monoclonal antibody, 1F7. Furthermore, these data suggest that IAP on
SS RBCs is structurally different from that expressed on AA RBCs but
that IAP expression levels do not vary between AA and SS RBCs. This
structural difference may contribute to the enhanced adhesion of SS
RBCs to immobilized TSP. These results identify IAP as a TSP receptor
on SS RBCs and suggest that this receptor and its binding site within
TSP represent potential therapeutic targets to decrease
vaso-occlusion.
(Blood. 2001;97:2159-2164) Sickle cell disease (SCD) epitomizes a genetic
disorder. A single DNA base mutation in the hemoglobin The characteristic manifestation of SCD, however, is the vaso-occlusive
crisis. This event accounts for most of the morbidity and mortality
associated with this condition and appears to result from blockage of
blood flow by SS RBCs.2 Patients in vaso-occlusive crisis
experience marked, localized pain arising from tissue hypoxia due to
inadequate perfusion from blocked vascular beds.3 The mechanisms by which vaso-occlusive crises are initiated are
largely unknown. However, data suggest that adhesion of SS
RBCs plays an important role in the overall vaso-occlusive
process.4
In vitro studies indicate that SS RBCs adhere to both activated
endothelial cells and exposed subendothelial matrix proteins that line
the blood vessel wall (reviewed in 5,6). Elevated plasma
factors, such as tumor necrosis factor- Chronic endothelial cell retraction and chronic vascular
injury12 in SCD potentially promote TSP expression in the
subendothelial matrix and subsequent exposure to the flowing SS RBCs.
In vitro evidence suggests that SS RBCs can adhere to TSP exposed in
endothelial cell gaps, thus supporting a role for matrix TSP as a
vascular adhesogen, potentially compounding
vaso-occlusion.13 Despite the relevance of TSP as an
adhesive molecule in SCD, the receptors that mediate SS RBC adhesion to
this vascular protein remain unknown.
TSP is a 450-kd glycoprotein homo-trimer with several adhesive domains.
Each chain contains an N-terminal domain that binds heparin sulfate
proteoglycans, a type 1 repeat that binds CD36 or glycoprotein IV
(GPIV), an RGD sequence that binds integrins, and a C-terminal
cell-binding domain that recognizes integrin-associated protein
(IAP).14-16 The cell-binding domain of TSP shares the
highest degree of homology among the thrombospondins Classically, IAP, or CD47, associates with and modulates integrin
function. However, IAP shows ubiquitous tissue and hematopoietic cell
distribution,21 including expression on mature
erythrocytes, cells that do not express integrins.22
Neither IAP expression nor a role for IAP on the SS RBC has ever been
demonstrated. Based on the role of IAP as an adhesion receptor for TSP
on other cells, we wanted to evaluate the adhesive potential of IAP on
SS RBCs for TSP.
We report here that IAP is expressed on SS RBCs and mediates a
significant proportion of SS RBC adhesion to TSP under flow and static
conditions. Additionally, we provide evidence that SS RBCs adhere to
the IAP binding site within the C-terminal cell-binding domain of TSP.
Furthermore, we provide evidence that the structure of IAP on SS RBCs
is different from the structure of IAP expressed on normal AA RBCs.
This structural change results in the decreased availability of one
monoclonal antibody (mAb) epitope on IAP and the potentiation of
another epitope. Despite this structural change, it appears that IAP
expression levels are similar or identical on SS and AA RBCs because no
difference in IAP expression levels could be detected with a polyclonal
antibody (pAb) or a separate mAb against this receptor. These data
therefore implicate IAP on sickle cells and the cell-binding domain of
TSP as mediators of SS RBC adhesion to subendothelial- and
endothelial-associated TSP in vivo.
Reagents
RBC preparation
Flow adhesion assay and protein-peptide immobilization The flow adhesion system used for this study was designed to mimic blood flow through postcapillary venules, as described.8,24 Purified TSP (80 µL of 18.75 µg/mL or 1.5 µg) or 4N1K, 4NGG, or 4N1KS peptide (198 nmol/well) in perfusion media was immobilized onto identical wells formed by the silicon gasket in a 35-mm polystyrene culture dish by incubating for 2 hours at 37°C. A 1% hematocrit solution (1.5 mL) was flowed over the wells at a rate of 1.0 mL/min and a constant shear stress of 1 dyne/cm2. After a wash period of approximately 4 minutes, the number of adherent cells from 4 representative areas of the well was counted from 0.25 cm2 fields and averaged. Any occasional adherent white blood cells were not included in the analysis.SS RBC static adhesion assay The static adhesion assay used for this study was based on an adenosine triphosphate (ATP) monitoring system, ATP-Lite (Packard Groningen, Netherlands). Microtiter plates (96-well) were coated with 1.5 µg TSP for 2 hours at 37°C and blocked for 30 minutes at 37°C with 0.3% BSA in Hanks balanced salt solution. SS RBCs (3 × 106) were added to each well and incubated for 2 hours at 37°C. Adherent cells were washed 4 times, and the remaining SS RBCs were lysed according to manufacturer's directions, transferred to Optiplate (Packard), and treated with ATP-Lite for luminescence measurement in a microtiter plate reader (TopCount; Packard).SS RBC Western blot analysis and indirect immunofluorescence SS and AA RBC membrane ghosts from 3 × 1010 cells were prepared by hypotonic lysis in 5 mM Na2HPO4 (pH, 8.0), 0.5 mM EGTA, and 2.0 mM phenylmethylsulfonyl fluoride. Washed intact membranes were then solubilized by a 20-minute incubation in 1% SDS, 1 mM EGTA, and 50 mM HEPES (pH, 7.4) at 95°C. The SDS soluble fraction essentially represented the entire membrane fraction and was loaded nonreduced onto SDS-PAGE, transferred to Immobilon-P (Millipore, Bedford, MD), and analyzed by Western blot with B6H12 mAb at 1 µg/mL, pAb against IAP, or anti-glycophorin A mAb (DAKO, Carpinteria, CA) at 1 µg/mL in Tris-buffered saline plus 0.1% Tween-20 (Sigma). Cell surface expression of IAP and saturating mAb concentrations were determined by immunostaining of washed SS RBCs with either the mAb 2D3 or the mAb 1F7 at various concentrations in perfusion media, followed by incubation with goat anti-mouse antibody conjugated to Cy3 (Jackson Immunoresearch, West Grove, PA). Stained samples were then analyzed by FACS-scan flow cytometry (Becton Dickinson, Franklin Lakes, NJ) gated to exclude any occasional white blood cells. Only RBCs of equivalent size, shape, and granularity were used in cell surface analysis of IAP expression.Density fractionation of RBCs For Western blotting and immunofluorescence of reticulocyte-enriched fractions of RBCs, unpacked, washed RBCs were layered over a modified arabino-galactan gradient (Larex, White Bear Lake, MN) and spun at 74 000g at 20°C for 45 minutes according to manufacturer's directions. RBCs collected from the low-density fraction of the gradient were subsequently analyzed for nuclear material content by methylene blue staining. Approximately 50% to 80% of the low-density fraction cells were identified as reticulocytes, representing an approximately 10-fold enrichment of reticulocytes in SS patients and an approximately 50-fold enrichment in AA donors.Analysis of immobilized peptides To determine the equivalent surface densities of the 4N1K, 4NGG, and 4N1KS peptides, varying concentrations of each peptide were adsorbed onto 96-well polystyrene culture plates for 2 hours at 37°C. Immobilized peptides were then washed in perfusion media and biotinylated at ambient temperature overnight in 10 mM EZ-Link PEO Maleimide Activated Biotin (Pierce, Rockford, IL), washed extensively in phosphate-buffered saline, and incubated for 1 hour with streptavidin-horse radish peroxidase conjugate. Peptide-bound biotin was then detected using the 3,3', 5'5-tetramethylbenzidine liquid substrate system (Sigma) and read at 450 nm in a microplate reader (Spectra Max Plus, Molecular Devices, Sunnyvale, CA).
To examine IAP expression on sickle RBCs, intact RBC membranes
from either SS or AA RBCs were solubilized in 1% SDS and analyzed by
Western blot with B6H12, an mAb against human IAP. B6H12 readily detected a band of approximately 52 kd, consistent with the established molecular weight of IAP21 in AA RBC membranes, but reacted
weakly with the same band from SS RBC membranes (Figure
1A, top). The results shown are
representative of 14 separate SS and AA samples each. However, a
polyclonal Ab against IAP detected equivalent amounts of IAP
solubilized from the same AA and SS RBC membranes (Figure 1A, middle)
under identical conditions, suggesting equivalent amounts of IAP in AA
and SS membrane samples. Additionally, Western blots of the same
samples with an anti-glycophorin A mAb showed no significant variation
in protein loading (Figure 1A, bottom). These results imply that the
SDS-denatured epitope for B6H12 is compromised in SS RBCs. This epitope
loss was present in every SS patient sample analyzed and strongly
suggested a unique structure or conformation of IAP on SS
RBCs.
To examine cell surface expression of IAP on SS RBCs, we immunostained
SS (n = 4) and AA (n = 4) RBCs with the mAbs 2D3 and 1F7 against
human IAP and analyzed RBC surface antibody binding by flow cytometry.
As shown in the representative histograms, saturating concentrations of
the 2D3 mAb exhibited increased fluorescence intensity of SS relative
to AA RBCs (Figure 1B, top), which could indicate an increased
availability of this epitope on SS RBCs. However, saturating
concentrations of 1F7 (1 µg/mL) bound both SS and AA RBCs in
equivalent amounts relative to an isotype-matched control IgG,
suggesting an equivalent availability of the 1F7 epitope on AA and SS
RBCs when IAP was in a native conformation in the plasma membrane
(Figure 1B, second panel). Additionally, increasing concentrations of
1F7 clearly showed that at each concentration, SS RBCs and AA RBCs
bound equivalent amounts of this antibody, further supporting
equivalent expression levels of IAP (Figure 1C). Taken together, these
results suggest that though it is expressed in equivalent amounts on SS
and AA RBCs, IAP on SS RBCs We previously demonstrated that the low-density, reticulocyte-enriched fraction of SS RBCs is the most adhesive to immobilized TSP under flow conditions.8 Therefore, we examined mAb binding and cell surface expression of IAP on this population of cells from both SS and AA donors. The difference in B6H12 reactivity on Western blots was observed in low-density, reticulocyte-enriched fractions of SS and AA RBCs (data not shown). The difference in 2D3 reactivity was observed as well; 2D3 bound preferentially to the SS reticulocyte-containing fraction compared to an equivalent population derived from AA donors (Figure 1B, third panel), further suggesting a different structure of IAP on these SS RBCs. However, by flow cytometry, both SS and AA low-density fractions bound equivalent amounts of 1F7 (Figure 1B, bottom), again suggesting equivalent cell surface expression on these immature cells. These results once more suggest that though IAP cell surface expression is equivalent among AA and SS RBCs of all ages, the structure of IAP on SS RBCs differs from that on AA RBCs. We next tested the hypothesis that IAP is an adhesion receptor on SS
RBCs for immobilized TSP. Using 1F7 to selectively block any IAP-TSP
interaction,22 we analyzed SS RBC adhesion to immobilized TSP under flow conditions. Pre-incubation of SS RBCs with saturating concentrations of 1F7, but not an isotype-matched control mAb (data not
shown), blocked SS RBC adhesion to TSP by approximately 50% in a
dose-dependent manner (Figure 2,
diamonds), suggesting that IAP on SS RBCs mediates a significant amount
of SS RBC adhesion to TSP under flow conditions. This result is not a
general effect of an antibody binding to the surface of the RBC or even
to IAP because antibodies against GPIV or glycophorin A, both of which bind SS RBCs, fail to inhibit adhesion to immobilized TSP under flow
conditions.8 Additionally, 2D3, a nonfunction blocking antibody that binds to IAP,25 failed to block SS RBC
adhesion to TSP at any concentration tested (Figure 2, squares),
suggesting that 1F7 specifically interrupts an IAP-TSP interaction.
These results suggest that IAP mediates a significant proportion of SS
RBC adhesion to TSP, and implicate IAP as an adhesion receptor on SS
RBCs.
Because IAP on other cell types binds to the RFYVVMWK sequence in the
cell-binding domain of TSP,23 we next asked whether this
sequence in TSP also supports SS RBC adhesion. Consequently, we
compared the binding of SS RBCs under flow to the immobilized 4N1K
peptide containing this IAP-binding sequence, the previously characterized 4NGG control peptide containing 2 conservative
mutations,23 or a scrambled 4N1K peptide termed 4N1KS
(Figure 3). Although both 4N1K and 4NGG
adsorbed equally to the plastic flow chamber and supported SS RBC
adhesion, the native sequence appeared to be most adhesive. SS RBC
adhesion to both immobilized peptides could be completely blocked by
pre-incubation of the SS RBCs with 1F7 but not a control mAb,
indicating an IAP-specific interaction with these peptides. In
contrast, the scrambled 4N1KS peptide failed to support SS RBC
adhesion, though this scrambled peptide adsorbed slightly better than
the 4N1K or 4NGG peptide to the solid-phase support (data not shown).
These results demonstrate a specific interaction of SS RBCs with a
peptide derived from the cell-binding domain of TSP. Finally, washed
RBCs from healthy controls failed to adhere to any of these peptides
under flow conditions (data not shown) even though they express IAP
(Figure 1). Taken together, these results indicate that a significant part of the mechanism by which sickle cells bind under basal flow conditions to immobilized TSP involves an interaction between IAP on
the sickle cells and the cell-binding domain of TSP.
During the vaso-occlusive crisis, it is likely that blood flow and
shear stress in an obstructed vessel become negligible. Therefore, we
studied the contribution of IAP to SS RBC adhesion to TSP immobilized
onto an identical substrate but in the absence of shear. Under static
conditions, saturating concentrations of 1F7 completely inhibited SS
RBC adhesion to immobilized TSP (Figure 4, diamonds). This percentage inhibition
was in contrast to our results under shear stress showing that 1F7
maximally inhibited adhesion by 49.5% (Figure 2, diamonds). An
isotype-matched control antibody had no effect on SS RBC adhesion to
TSP (Figure 4, circles). These results strongly suggest that IAP
binding to the cell-binding domain in TSP may mediate SS RBC adhesion
to the blood vessel wall in free-flowing vessels and under static
conditions, proximal to an already formed vaso-occlusion.
In this work, we provide evidence that IAP serves as an adhesion receptor on SS RBCs for immobilized TSP, a conformation of TSP thought to mimic matrix TSP or TSP adherent to the endothelium. We demonstrate that IAP is expressed on SS RBCs in amounts similar to those on AA RBCs but that the structure-conformation of IAP on SS RBCs is altered from that expressed on normal AA RBCs. We also show that the selective blockade of this receptor blocks SS RBC adhesion to immobilized TSP under flow conditions by approximately 50%, whereas the disruption of IAP function under static conditions results in a virtual ablation of SS RBC adhesion to immobilized TSP. Additionally, the IAP binding site within the C-terminal cell-binding domain of TSP supports SS RBC adhesion under flow conditions, implicating this adhesive sequence as a sickle cell binding site within TSP and supporting an adhesive role for IAP on SS RBCs. Our data also suggest that IAP on the SS RBCs is structurally different
than that expressed on AA RBCs, based on the relative loss of the
denatured B6H12 epitope and the potentiation of 2D3 binding to the
surface of SS RBCs compared to AA RBCs (Figure 1). Although it is
intriguing to speculate that this change in antibody binding and the
inferred structural difference in IAP on SS RBCs is solely responsible
for a gain of IAP function on the SS RBCs, we are considering this
possibility along with several other models. In the first model, we
propose that expression of IAP is necessary, but not sufficient, to
confer maximal SS RBC adhesion to TSP under flow conditions. We
speculate that IAP-mediated adhesion under flow is also dependent on
other TSP receptors expressed on SS RBCs, thus providing one
explanation of the incomplete inhibition of adhesion by 1F7 under flow,
even at saturating concentrations of this antibody. These other as yet
unidentified, but necessary, receptors may serve to bind TSP, provide
multiple adhesive contacts, and synergize with IAP to firmly anchor the
SS RBC to TSP under shear stress. Studies of density-separated
subpopulations of SS RBCs show that adhesion to TSP under flow is
enhanced in the immature SS reticulocyte-enriched fraction of SS
RBCs.8 Analysis of the same fraction of SS RBCs using flow
cytometry also demonstrates that these "younger" cells express the
TSP receptor CD36 or GPIV, as well as integrin
It is interesting that SS RBC adhesion to TSP appears to be more sensitive to 1F7 inhibition under static conditions. In fact, saturating concentrations of 1F7 ablate SS RBC adhesion to TSP in the absence of shear (Figure 4, diamonds). This result may indicate that fewer adhesive contacts are required to sustain adhesion under static conditions and that the IAP-TSP interaction is sufficient in number and avidity to sustain stable adhesion to TSP in the absence of shear. Under flow conditions, however, 1F7 may be less efficient in disrupting the IAP-TSP interaction or may fail to bind all IAP sites. As a result, only a partial inhibition of SS RBC adhesion is observed under flow. The loss of the denatured B6H12 epitope and the potentiation of 2D3 binding exclusively on SS RBCs clearly suggest a consistent difference between the structure of IAP on these cells versus AA RBCs. Therefore, another model of IAP's role on SS RBCs is that this structural change confers a gain of IAP function, namely enhanced RBC avidity for immobilized TSP. In support of this model, only SS RBCs, but not AA RBCs, adhere in an IAP-dependent manner to the immobilized IAP ligands (the 4N1K peptide derived from the cell-binding domain of TSP or TSP itself), even though both sets of RBCs express equivalent amounts of IAP. Therefore, an inference can be made that the structure or conformation of IAP on SS RBCs relative to AA RBCs more readily supports RBC adhesion under flow and static conditions. Based on the structural gain of function model, it is tempting to
speculate about the nature of the change between IAP on SS RBCs versus
AA RBCs. The consistent difference in the structure of IAP between SS
RBCs and AA RBCs could represent a linked polymorphism between the gene
for IAP and expression of HbS. However, we hypothesize that any changes
in IAP most likely result from differences in enzymatic and/or
nonenzymatic, post-translational modification of IAP in SS patients.
IAP has an immunoglobulin variable-like amino-terminal extracellular
domain, followed by a predicted 5-membrane spanning region and a short
cytoplasmic, carboxy-terminal region.21 IAP contains 6 N-linked glycosylation sites, 5 of which are in the immunoglobulin
variable region Our data also identify the cell-binding domain of TSP as an adhesive sequence to which SS RBCs can bind under flow conditions. This result is consistent with that of Hillery et al,29 who demonstrated that the C-terminal domain of TSP is required for SS RBC adhesion, and it suggests that the identification of this sequence can be therapeutically exploited in SCD as an inhibitor of SS RBC adhesion to components in the vascular wall. Additionally, this adhesive sequence is present in the matrix molecule laminin,19,20,23 a molecule to which SS RBCs adhere under flow conditions,24 and it is elevated in the plasma of SCD patients.30 Thus, our results suggest that the TSP sequence indicated by the 4N1K peptide could represent a major adhesive and regulatory sequence for SS RBC adhesion in vivo. In summary, our results suggest that IAP may be a major adhesion receptor on SS RBCs for the vascular protein TSP under flow and static conditions. We have further identified the site in TSP to which IAP binds as the cell-binding domain of this adhesive protein. Significantly, we have demonstrated that IAP on SS RBCs is structurally different from that expressed on AA RBCs. We speculate that this structural change may contribute directly to SS RBC adhesion in SCD and may, therefore, contribute to vaso-occlusion in this chronic illness. Although our studies thus far have identified IAP and the cell-binding domain of TSP as novel therapeutic targets in SCD, future studies promise to fully elucidate mechanisms of SS RBC adhesion, protein expression, and vaso-occlusion in SCD.
We thank Patrick Hines, Tina Leisner, E. M. Pickens, and David Shock for their assistance, support, and technical expertise in the preparation of this manuscript. In addition, we thank Jim Thompson, Dell Strayhorn, Susan Jones, and Jamie Hodges at the University of North Carolina Comprehensive Sickle Cell Center for their help in patient recruitment.
Submitted February 23, 2000; accepted December 6, 2000.
Supported by HL58939 (L.V.P.) and RR00046 (E.P.O.) from the National Institutes of Health.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Leslie V. Parise, Dept of Pharmacology, The University of North Carolina at Chapel Hill, CB#7365, Chapel Hill, NC 27599; e-mail: parise{at}med.unc.edu.
1. Ballas SK, Mohandas N. Pathophysiology of vaso-occlusion. Hematol Oncol Clin North Am. 1996;10:1221-1239[CrossRef][Medline] [Order article via Infotrieve]. 2. Hillery CA. Potential therapeutic approaches for the treatment of vaso-occlusion in sickle cell disease. Curr Opin Hematol. 1998;5:151-155[Medline] [Order article via Infotrieve]. 3. Cherry-Peppers G, Davis V, Atkinson JC. Sickle-cell anemia: a case report and literature review. Clin Prev Dent. 1992;14:5-9[Medline] [Order article via Infotrieve]. 4. Hebbel R, Boogarets M, Eaton J, Steinberg M. Erythrocyte adherence to the endothelium in sickle cell anemia: a possible determinant of disease severity. N Engl J Med. 1980;302:1992. 5. Hebbel RP. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest. 1997;100:S83-S86. 6. Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol. 1996;3:118-124[Medline] [Order article via Infotrieve].
7.
Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA.
Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis.
Blood.
1998;92:2551-2555
8.
Joneckis CC, Shock DD, Cunningham ML, Orringer EP, Parise LV.
Glycoprotein IV-independent adhesion of sickle red blood cells to immobilized thrombospondin under flow conditions.
Blood.
1996;87:4862-4870
9.
Brittain HA, Eckman JR, Swerlick RA, Howard RJ, Wick TM.
Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: a potential role for platelet activation in sickle cell vaso-occlusion.
Blood.
1993;81:2137-2143
10.
Sugihara K, Sugihara T, Mohandas N, Hebbel RP.
Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells.
Blood.
1992;80:2634-2642 11. Browne PV, Mosher DF, Steinberg MH, Hebbel RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol. 1996;51:296-301[CrossRef][Medline] [Order article via Infotrieve].
12.
Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP.
Circulating activated endothelial cells in sickle cell anemia.
N Engl J Med.
1997;337:1584-1590
13.
Manodori AB, Matsui NM, Chen JY, Embury SH.
Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation.
Blood.
1998;92:3445-3454 14. Mosher D. Physiology of thrombospondin. Annu Rev Med. 1990;41:85-97[CrossRef][Medline] [Order article via Infotrieve].
15.
Lawler J.
The structural and functional properties of thrombospondin.
Blood.
1986;67:1197-1209
16.
Frazier W.
Thrombospondin: a modular adhesive glycoprotein of platelets and nucleated cells.
J Cell Biol.
1987;105:625-632 17. Adams J, Tucker R, Lawler J. The Thrombospondin Gene Family. Austin, TX: RG Landis; 1995.
18.
Dixit V, Haverstick D, O'Rouke K, et al.
A monoclonal antibody against human thrombospondin inhibits platelet aggregation.
Proc Natl Acad Sci U S A.
1985;82:3472-3476
19.
Kosfeld M, Frazier W.
Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin.
J Biol Chem.
1993;268:8808-8814
20.
Kosfield M, Pavlopoulos T, Frazier W.
Cell attachment activity of the carboxyl-terminal domain of human thrombospondin expressed in Escherichia coli.
J Biol Chem.
1991;266:24257-24259
21.
Lindberg FP, Gresham HD, Schwarz E, Brown EJ.
Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in 22. Rosales C, Gresham HD, Brown EJ. Expression of the 50-kDa integrin-associated protein on myeloid cells and erythrocytes. J Immunol. 1992;149:2759-2764[Abstract].
23.
Gao AG, Lindberg FP, Finn MB, Blystone SD, Brown EJ, Frazier WA.
Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin.
J Biol Chem.
1996;271:21-24
24.
Lee SP, Cunningham ML, Hines PC, Joneckis CC, Orringer EP, Parise LV.
Sickle cell adhesion to laminin: potential role for the
25.
Pettersen RD, Hestdal K, Olafsen MK, Lie SO, Lindberg FP.
CD47 signals T cell death.
J Immunol.
1999;162:7031-7040
26.
Joneckis CC, Ackley RL, Orringer EP, Wayner EA, Parise LV.
Integrin
27.
Swerlick R, Eckman J, Kumar A, Jeitler M, Wick T.
28. Mawby WJ, Holmes CH, Anstee DJ, Spring FA, Tanner MJ. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J. 1994;304:525-530.
29.
Hillery CA, Scott JP, Du MC.
The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion.
Blood.
1999;94:302-309 30. Bolarin DM, Swerdlow P, Wallace AM, Littsey L. Serum concentrations of laminin P1 and aminoterminal propeptide of type III procollagen in sickle cell disease. Haematologia (Budap). 1998;29:51-58[Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  B. N. Y. Setty and S. G. Betal Microvascular endothelial cells express a phosphatidylserine receptor: a functionally active receptor for phosphatidylserine-positive erythrocytes Blood, January 15, 2008; 111(2): 905 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Kaul, X.-d. Liu, X. Zhang, T. Mankelow, S. Parsons, F. Spring, X. An, N. Mohandas, D. Anstee, and J. A. Chasis Peptides based on {alpha}V-binding domains of erythrocyte ICAM-4 inhibit sickle red cell-endothelial interactions and vaso-occlusion in the microcirculation Am J Physiol Cell Physiol, November 1, 2006; 291(5): C922 - C930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mandle, H. Einsele, M. Schaller, D. Neumann, W. Vogel, I. B. Autenrieth, and V. A. J. Kempf Infection of human CD34+ progenitor cells with Bartonella henselae results in intraerythrocytic presence of B henselae Blood, August 15, 2005; 106(4): 1215 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Brittain, J. Han, K. I. Ataga, E. P. Orringer, and L. V. Parise Mechanism of CD47-induced {alpha}4{beta}1 Integrin Activation and Adhesion in Sickle Reticulocytes J. Biol. Chem., October 8, 2004; 279(41): 42393 - 42402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Wandersee, S. C. Olson, S. L. Holzhauer, R. G. Hoffmann, J. E. Barker, and C. A. Hillery Increased erythrocyte adhesion in mice and humans with hereditary spherocytosis and hereditary elliptocytosis Blood, January 15, 2004; 103(2): 710 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Watkins, L. M. Du, J. P. Scott, W. H. Ouwehand, and C. A. Hillery Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion Blood, July 15, 2003; 102(2): 718 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-T. Fujimoto, S. Katsutani, T. Shimomura, and K. Fujimura Thrombospondin-bound Integrin-associated Protein (CD47) Physically and Functionally Modifies Integrin {alpha}IIb{beta}3 by Its Extracellular Domain J. Biol. Chem., July 11, 2003; 278(29): 26655 - 26665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Matsui, A. Varki, and S. H. Embury Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin Blood, November 15, 2002; 100(10): 3790 - 3796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Y. Setty, S. Kulkarni, and M. J. Stuart Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion Blood, March 1, 2002; 99(5): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Garratty, M. J. Telen, and L. D. Petz Red Cell Antigens as Functional Molecules and Obstacles to Transfusion Hematology, January 1, 2002; 2002(1): 445 - 462. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
chain
results in a single amino acid change (glu
val). This
mutated hemoglobin, termed hemoglobin S, or HbS, forms rigid,
intracellular, insoluble polymers, causing the affected red blood cell
(RBC) to assume the characteristic sickle shape presented in SCD.
Patients homozygous for hemoglobin S (SS) exhibit a complex host of
clinical symptoms. Manifestations of SCD include marked, chronic
hemolysis and anemia, acute chest syndrome, susceptibility to
infection, stroke, retinopathy, and splenic sequestration
crisis.
, platelet-activating factor
(PAF), histamine, and IL-8, are thought to up-regulate the
adhesive state of endothelial cells for SS RBCs.
more than any
other adhesive site in the molecule
-amino
groups, which is known to occur in some proteins. Because of low oxygen
tension, repeated ischemia-reperfusion injury, and hosts of other
chronic vascular injuries and anemia in SS patients, it is likely that
essential enzymes linked to protein processing have altered activity in
SCD, potentially resulting in the expression of altered cellular
proteins. The amino acid sequence of IAP, or other integral membrane
proteins, has never been examined in SCD. Therefore, studies are under
way to determine the exact nature of the change in IAP in this disease,
and these studies may lead to the identification of several other
abnormal modifier proteins in SCD.